A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Plain-language summary

This study evaluates the combination of oral PF-00299804 with intravenous CP-751,871 in patients with advanced cancer. It included patients with confirmed advanced cancer in adequate general condition. It was a Phase 1 study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Completed

Sponsor

Pfizer

Intervention

PF-00299804

Start date

12/15/2008

Estimated completion

1/29/2013

Countries

United States, France, Spain

Related genes

Locations

• Amherst, United States
• Buffalo, United States
• San Antonio, United States
• Villejuif, France
• Madrid, Spain

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Histologically documented advanced cancer, Eastern Cooperative Oncology Group (ECOG) 0-1;
* Platelets \> 100,000, ANC \> 1500;
* Ccr \> 60 or serum creat. \<1.5
* Non-small cell cancer cohort:
* Eastern Cooperative Oncology Group (ECOG) 0-2, prior platin, \< 4 prior chemotherapy regimen
* HgA1C \<5.7%

Exclusion Criteria:

* Active Central Nervous System (CNS) metastases;
* prior IGF1-R targeted therapy
* Any history of unstable angina, myocardial infarction or symptomatic congestive heart failure.